CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Jul. 02, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents		$ 2,632	$ 416
Short-term investments		42,153	22,316
Trade accounts receivable, less allowance for doubtful accounts: 2023—$471; 2022—$449		10,231	10,952
Inventories	[1]	10,310	8,981
Current tax assets		3,194	3,577
Other current assets		4,828	5,017
Total current assets		73,347	51,259
Equity-method investments		11,422	11,033
Long-term investments		3,644	4,036
Property, plant and equipment, less accumulated depreciation: 2023—$15,554; 2022—$15,174		17,488	16,274
Identifiable intangible assets	[2]	41,406	43,370
Goodwill		51,572	51,375
Noncurrent deferred tax assets and other noncurrent tax assets		8,261	6,693
Other noncurrent assets		13,028	13,163
Total assets		220,168	197,205
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2023—$3,565; 2022—$2,560		3,985	2,945
Trade accounts payable		6,081	6,809
Dividends payable		2,315	2,303
Income taxes payable		2,928	1,587
Accrued compensation and related items		1,972	3,407
Deferred revenues		1,286	2,520
Other current liabilities		16,079	22,568
Total current liabilities		34,647	42,138
Long-term debt		61,356	32,884
Pension and postretirement benefit obligations		2,184	2,250
Noncurrent deferred tax liabilities		1,232	1,023
Other taxes payable		8,052	9,812
Other noncurrent liabilities		13,403	13,180
Total liabilities		120,875	101,288
Commitments and Contingencies
Common stock		478	476
Additional paid-in capital		92,329	91,802
Treasury stock		(114,482)	(113,969)
Retained earnings		128,796	125,656
Accumulated other comprehensive loss		(8,102)	(8,304)
Total Pfizer Inc. shareholders’ equity		99,019	95,661
Equity attributable to noncontrolling interests		274	256
Total equity		99,293	95,916
Total liabilities and equity		$ 220,168	$ 197,205

[1] The increase from December 31, 2022 reflects higher inventory levels for Paxlovid and, to a lesser extent, increases for certain products due to supply recovery and inventory build, partially offset by decreases due to net market demand.

[2] The decrease is primarily due to amortization expense of $2.3 billion and impairments of $248 million (see Note 4), partially offset by additions of $681 million mostly related to milestone payments for the approvals in the U.S. for Zavzpret nasal spray and Ngenla.